Founded in 1992, Onyx Pharmaceuticals Inc. in Emeryville, Calif., has 275 employees. It developed and sells Nexavar, a drug that treats liver and kidney cancer. Worldwide sales of the drug last year reached $844 million; company revenue was $251 million in 2009. Onyx has an agreement with Bayer Corp. to share development expenses and profits in nearly all countries.
Onyx last year acquired Proteolix Inc. and with it a late-stage clinical molecule called carfilzomib to treat blood cancer. Carfilzomib is in clinical trials and is expected to be available next year.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
